Back to Search
CHARLES CHESNUT, MD
MD
Nuclear Medicine Physician
NPI: 1609952456Individual
Specialties, Licenses & Credentials
Nuclear Medicine PhysicianPrimary
Nuclear Medicine
Code: 207U00000X
MD00011188(WA)
Research & Publications (20)
Salmon calcitonin: a review of current and future therapeutic indications.
PMID 18071651·Osteoporos Int·2008
6-review
Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
PMID 16903769·Drugs·2006
6-review
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
PMID 16059627·J Bone Miner Res·2005
7-preclinical
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
PMID 15811208·Curr Med Res Opin·2005
3-trial
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
PMID 15231010·J Bone Miner Res·2004
3-trial
The relationship between skeletal and oral bone mineral density: an overview.
PMID 11887464·Ann Periodontol·2001
6-review
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
PMID 11760829·J Bone Miner Res·2001
6-review
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
PMID 10996576·Am J Med·2000
3-trial
Assessment of bone quality, quantity, and turnover with multiple methodologies at multiple skeletal sites.
PMID 11783630·Adv Exp Med Biol·2001
3-trial
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
PMID 18056047·Ann N Y Acad Sci·2007
6-review
Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease.
PMID 17531778·Biol Blood Marrow Transplant·2007
4-observational
Denosumab in postmenopausal women with low bone mineral density.
PMID 16495394·N Engl J Med·2006
3-trial
Review of treatment modalities for postmenopausal osteoporosis.
PMID 16295815·South Med J·2005
6-review
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
PMID 15977464·Aging Clin Exp Res·2005
3-trial
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
PMID 15121021·Bone·2004
3-trial
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
PMID 15071723·Osteoporos Int·2004
3-trial
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
PMID 14753731·J Bone Miner Res·2004
3-trial
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
PMID 14727011·Osteoporos Int·2004
3-trial
Short-term calcium supplementation has no effect on biochemical markers of bone remodeling in early postmenopausal women.
PMID 14648073·Arch Gynecol Obstet·2004
3-trial
Bone remodeling and bone mineral density during pregnancy.
PMID 14504876·Arch Gynecol Obstet·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- UWMC-ROOSEVELT, 4245 ROOSEVELT WAY NE
SEATTLE, WA 98105 - Phone
- (206) 598-4288
Quick Facts
- NPI
- 1609952456
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile